Fundamental Data for THRX

THERAVANCE(NSDQ:THRX)

Theravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.

# Employees: 191

Address: 901 Gateway Boulevard,South San Francisco,CA,USA

Phone: 650 808-6000

Fax: 650-827-8690

Website: www.theravance.com

Email: investor.relations@theravance.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Roy P. Vagelos M.D. (Chmn.)

Michael W. Aguiar (Sr. V.P. Fin.; C.F.O. & Princ. Acctg. Off.)

Rick E. Winningham (C.E.O.; Dir.)

Robert V. Gunderson Jr. (Dir.)

Jeffrey M. Drazan (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/11/2010

Mean EPS (Next Qtr): ($0.33)

Mean EPS (Year): ($1.32)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 9

Shares Performance

Period	THRX	Compare to S&P
YTD	13.32 %	-6.22 %
4 Weeks	-6.46 %	-7.47 %
12 Weeks	-10.80 %	-15.90 %

Shares Information

Analyst Coverage: Y

Avg Volume: 265522

Shares Outstanding: 63M

Market Cap: $0.89B

52 Week High: $18.48

52 Week Low: $5.77

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 THRX split by factor of 0.200

Earnings Performance

EPS Growth in Last Quarter: 0.00 %

EPS Growth in Last Year: -2.94 %

Sales Growth in Last Quarter: 0.40 %

Sales Growth in Last Quarter: -8.07 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 33.680